ZYME

Zymeworks Inc. (ZYME) | Rumor.io

Zymeworks

ZYME

Attention (50-day avg)0%

Attention rank (50-day avg)#1,827

Bullish sentiment (50-day avg)92%

Price to earnings ratio3.79

Market capitalization1.9B

Earnings per share-2.02

Dividend yield (TTM)—

Revenue (annual)106M

Net income (annual)-81.1M

Social

What share of all stock conversation is about ZYME?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% 0

Aug 25

Zymeworks' Ziihera has been approved by the FDA for first-line HER2-positive gastroesophageal adenocarcinoma, with a $250M milestone payment triggered for the company.
The approval is a result of Zymeworks licensing out zanidatamab, a bispecific antibody aimed at HER2-positive cancers, to Jazz Pharmaceuticals.
The company retains royalties on Ziihera sales, in addition to the milestone payment, providing a potential source of future revenue.

Generated by AI

Sentiment

Of the messages about ZYME that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100% 0	97.3% +10.81	86.94% +1.25
Bearish	0%	0% 0	2.7% -10.81	13.06% -1.25

Bullish· Nov 17

Zymeworks delivered a clean Phase 3 win against trastuzumab in 1L HER2-positive gastric/GEA, making it a potential competitor in the market.
The company's impressive results have led to a significant increase in its stock price, with a potential for further growth to $100+.
Zymeworks' platform has expanded its market potential in the billions, with a lucrative HER2+ breast cancer market within its sights.

Bearish· Dec 21

The company's cash per share payout and reduced burn rate may not be enough to boost the stock, as seen in the delayed reaction to the news.
The $320M payment for the company may not be enough to justify its current market cap, leading to potential further declines.
The company's stock has been subject to manipulation, and the pessimist's outlook is that it may trade below $8 again.

Generated by AI

Topics

Of the messages about ZYME that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	75.79%	70.82%
Technical Analysis	0%	0%	24.21%	8.78%
Analysts	0%	0%	0%	11.13%
Earnings	0%	0%	0%	2.56%
Controversies	0%	0%	0%	0.28%
Macro	0%	0%	0%	6.43%

Earnings· Mar 14

Zymeworks Inc. reported Q4 earnings per share (EPS) of $1.28.
This represents a significant beat on earnings expectations.
$ZYME's Q4 results may indicate a positive trend for the company.

Announcements· Jun 29

Zymeworks Inc. ($ZYME) has entered into a definitive agreement to acquire Theravance Biopharma ($TBPH) for $17 per share in cash, representing an equity value of approximately $929 million.
The deal includes a contingent value right (CVR) for future ampreloxetine proceeds and adds YUPELRI to Zymeworks' portfolio.
The acquisition is primarily financed by a $350 million non-recourse note, with the remaining $360 million coming from Theravance Biopharma's net cash on balance sheet and $219 million from Zymeworks.

Technical Analysis· Oct 19

$ZYME has turned positive with its monthly and 6-monthly indicators, suggesting a potential buying opportunity.
The stock's bulls are attempting to break the key weekly level of 6.44, with aggressive bears looking to short at 6.84.
$ZYME's trend line looks beautiful, with the stock's bulls testing 6.44 weekly resistance and the bears hoping to confirm a head and shoulders reversal pattern.

Generated by AI

Community

Of the messages about ZYME, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	67.57%	54.32%	60.44%
Newcomers	100%	32.43%	45.68%	39.56%

Regulars· Aug 25

Zymeworks Inc.'s ($ZYME) zanidatamab-hrii (Ziihera) has been approved as a first-line treatment for HER2-positive gastroesophageal adenocarcinoma (GEA).
The approval triggers a $250M milestone payment and Zymeworks is expected to continue its buying back shares to maximize the amount it can take off the market.
Regular participants are optimistic about the stock's future, with some predicting it will reach $40 by year-end.

Newcomers· Aug 25

New investors are excited about the FDA approval of Ziihera, a drug developed by Zymeworks, which triggers a $250M milestone payment and royalties on sales.
The approval is seen as a catalyst for Zymeworks' stock, with some investors predicting further gains, while others are concerned about a potential sell-off on the news.
There are questions and uncertainty about the recent price drop, with some investors wondering if there is a reason for the decline despite the positive news about the FDA approval.

Generated by AI

News

Zymeworks stock rating maintained at outperform by Citizens

1d agoInvesting.com

Zymeworks Updates Annual Financial Targets After Finalizing Theravance Biopharma Deal - Zymeworks (NASDAQ

Zymeworks completes its Theravance Biopharma acquisition, boosts 2026 revenue guidance, and gains recurring revenue from YUPELRI sales.

1d agoBenzinga

Zymeworks Inc. (ZYME) Theravance Biopharma, Inc. - M&A Call - Slideshow (NASDAQ:ZYME) 2026-09-28

1d agoSeeking Alpha

Zymeworks Completes Acquisition of Theravance Biopharma; Updates 2026 Guidance

Zymeworks (ZYME) said Monday it has completed its acquisition of Theravance Biopharma, adding Yupelr

2d agoYahoo Finance

Zymeworks Completes Acquisition of Theravance Biopharma

Zymeworks (ZYME) said late Wednesday it completed its previously announced $929 million acquisition

6d agoYahoo Finance

Theravance Biopharma shareholders approve merger with Zymeworks

11d agoInvesting.com

Also Discussed

Investors talking about ZYME also mention

#	Name	Attention
1	Genmab A/S American Depositary SharesGMAB	0%0
2	BPMC - Blueprint Medicines Corporation	——
3	RPTX - Repare Therapeutics Inc.	——
4	Bicycle Therapeutics plc - ADRBCYC	0%0
5	IDEAYA Biosciences Inc.IDYA	0%-0.01
6	FNCH - Finch Therapeutics Group, Inc.	——
7	SWTX - SpringWorks Therapeutics, Inc.	——
8	YMAB - Y-mAbs Therapeutics, Inc.	——
9	NextCure, Inc.NXTC	0%0
10	Pacer Nasdaq-100 Top 50 Cash Cows Growth Leaders ETFQQQG	0%0

Zymeworks Inc.

Healthcare
Biotechnology

Zymeworks Inc. is a biotechnology company focused on discovering, developing, and commercializing multifunctional biotherapeutics for difficult-to-treat diseases. Its current work centers on oncology and other serious conditions, including inflammation and autoimmune disorders, using advanced antibody-based platforms designed to create highly differentiated drug candidates. The company’s portfolio includes licensed healthcare assets as well as clinical and preclinical programs, with products and candidates such as Ziihera and pasritamig among its notable programs. Zymeworks also develops antibody-drug conjugates and multispecific therapeutics, reflecting a broader strategy of combining proprietary platforms with partnered assets to address unmet medical needs. The company plays a specialized role in the biopharmaceutical market by advancing targeted therapies that aim to improve treatment options across cancer and immunology-focused segments.

Website

Location

108 Patriot Drive

Middletown, DE, 19709

United States

Social

What share of all stock conversation is about ZYME?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% 0

Aug 25

Zymeworks' Ziihera has been approved by the FDA for first-line HER2-positive gastroesophageal adenocarcinoma, with a $250M milestone payment triggered for the company.
The approval is a result of Zymeworks licensing out zanidatamab, a bispecific antibody aimed at HER2-positive cancers, to Jazz Pharmaceuticals.
The company retains royalties on Ziihera sales, in addition to the milestone payment, providing a potential source of future revenue.

Generated by AI

Sentiment

Of the messages about ZYME that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100% 0	97.3% +10.81	86.94% +1.25
Bearish	0%	0% 0	2.7% -10.81	13.06% -1.25

Bullish· Nov 17

Zymeworks delivered a clean Phase 3 win against trastuzumab in 1L HER2-positive gastric/GEA, making it a potential competitor in the market.
The company's impressive results have led to a significant increase in its stock price, with a potential for further growth to $100+.
Zymeworks' platform has expanded its market potential in the billions, with a lucrative HER2+ breast cancer market within its sights.

Bearish· Dec 21

The company's cash per share payout and reduced burn rate may not be enough to boost the stock, as seen in the delayed reaction to the news.
The $320M payment for the company may not be enough to justify its current market cap, leading to potential further declines.
The company's stock has been subject to manipulation, and the pessimist's outlook is that it may trade below $8 again.

Generated by AI

Topics

Of the messages about ZYME that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	75.79%	70.82%
Technical Analysis	0%	0%	24.21%	8.78%
Analysts	0%	0%	0%	11.13%
Earnings	0%	0%	0%	2.56%
Controversies	0%	0%	0%	0.28%
Macro	0%	0%	0%	6.43%

Earnings· Mar 14

Zymeworks Inc. reported Q4 earnings per share (EPS) of $1.28.
This represents a significant beat on earnings expectations.
$ZYME's Q4 results may indicate a positive trend for the company.

Announcements· Jun 29

Zymeworks Inc. ($ZYME) has entered into a definitive agreement to acquire Theravance Biopharma ($TBPH) for $17 per share in cash, representing an equity value of approximately $929 million.
The deal includes a contingent value right (CVR) for future ampreloxetine proceeds and adds YUPELRI to Zymeworks' portfolio.
The acquisition is primarily financed by a $350 million non-recourse note, with the remaining $360 million coming from Theravance Biopharma's net cash on balance sheet and $219 million from Zymeworks.

Technical Analysis· Oct 19

$ZYME has turned positive with its monthly and 6-monthly indicators, suggesting a potential buying opportunity.
The stock's bulls are attempting to break the key weekly level of 6.44, with aggressive bears looking to short at 6.84.
$ZYME's trend line looks beautiful, with the stock's bulls testing 6.44 weekly resistance and the bears hoping to confirm a head and shoulders reversal pattern.

Generated by AI

Community

Of the messages about ZYME, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	67.57%	54.32%	60.44%
Newcomers	100%	32.43%	45.68%	39.56%

Regulars· Aug 25

Zymeworks Inc.'s ($ZYME) zanidatamab-hrii (Ziihera) has been approved as a first-line treatment for HER2-positive gastroesophageal adenocarcinoma (GEA).
The approval triggers a $250M milestone payment and Zymeworks is expected to continue its buying back shares to maximize the amount it can take off the market.
Regular participants are optimistic about the stock's future, with some predicting it will reach $40 by year-end.

Newcomers· Aug 25

New investors are excited about the FDA approval of Ziihera, a drug developed by Zymeworks, which triggers a $250M milestone payment and royalties on sales.
The approval is seen as a catalyst for Zymeworks' stock, with some investors predicting further gains, while others are concerned about a potential sell-off on the news.
There are questions and uncertainty about the recent price drop, with some investors wondering if there is a reason for the decline despite the positive news about the FDA approval.

Generated by AI

Zymeworks

Social

Aug 25

Bullish· Nov 17

Bearish· Dec 21

Earnings· Mar 14

Announcements· Jun 29

Technical Analysis· Oct 19

Regulars· Aug 25

Newcomers· Aug 25

Zymeworks stock rating maintained at outperform by Citizens

Zymeworks Updates Annual Financial Targets After Finalizing Theravance Biopharma Deal - Zymeworks (NASDAQ

Zymeworks Inc. (ZYME) Theravance Biopharma, Inc. - M&A Call - Slideshow (NASDAQ:ZYME) 2026-09-28

Zymeworks Completes Acquisition of Theravance Biopharma; Updates 2026 Guidance

Zymeworks Completes Acquisition of Theravance Biopharma

Theravance Biopharma shareholders approve merger with Zymeworks

Also Discussed

Zymeworks Inc.

Company Information

Location

Zymeworks stock rating maintained at outperform by Citizens

Zymeworks Updates Annual Financial Targets After Finalizing Theravance Biopharma Deal - Zymeworks (NASDAQ

Zymeworks Inc. (ZYME) Theravance Biopharma, Inc. - M&A Call - Slideshow (NASDAQ:ZYME) 2026-09-28

Zymeworks Completes Acquisition of Theravance Biopharma; Updates 2026 Guidance

Zymeworks Completes Acquisition of Theravance Biopharma

Theravance Biopharma shareholders approve merger with Zymeworks

Also Discussed

Social

Aug 25

Bullish· Nov 17

Bearish· Dec 21

Earnings· Mar 14

Announcements· Jun 29

Technical Analysis· Oct 19

Regulars· Aug 25

Newcomers· Aug 25